FDA Grants an Investigational Device Exemption for Trial Evaluating AlucentNVS Technology for Promoting the Maturation of Arteriovenous Fistulas.

U.S. FDA grants an investigational device exemption for trial evaluating Novel AlucentNVS Technology Read more

Alucent Biomedical Announces First Patient Enrolled in the First-in-Human Clinical Trial of Its Novel AlucentNVS Technology for Arteriovenous Fistula (AVF) in People with End Stage Renal Disease (ESRD)

First Patient Enrolled in First in Human Natural Vascular Scaffolding Clinical Trial. 

Funding Will Support Clinical Trials to Evaluate the Company’s Novel Treatment for Peripheral Artery Disease